Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'

Executive Summary

Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.

Advertisement

Related Content

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Pipeline Watch: Phase III Top-Line Data With Givosiran, Soliris and Vascepa
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Kala Hopes To Stride Into Dry Eye Market This Year
GW CEO: Cannabinoid Platform Is Growth Engine Beyond Epidiolex
Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel